These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36686301)

  • 1. Fluoro-2-Deoxyglucose-Positron Emission Tomography/Computed Tomography in the Diagnosis and Management of Adrenocortical Carcinoma: A 10-Year Experience from a Tertiary Care Institute.
    Krishnaraju VS; Kumar R; Subramanian K; Mittal BR; Singh H; Chatterjee D; Walia R
    Indian J Nucl Med; 2022; 37(3):227-235. PubMed ID: 36686301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients.
    Takeuchi S; Balachandran A; Habra MA; Phan AT; Bassett RL; Macapinlac HA; Chuang HH
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2066-73. PubMed ID: 24990404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.
    Ardito A; Massaglia C; Pelosi E; Zaggia B; Basile V; Brambilla R; Vigna-Taglianti F; Duregon E; Arena V; Perotti P; Penna D; Terzolo M
    Eur J Endocrinol; 2015 Dec; 173(6):749-56. PubMed ID: 26346137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of
    Ozturk H
    Rep Pract Oncol Radiother; 2023; 28(6):728-736. PubMed ID: 38515818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
    Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
    Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.
    Werner RA; Kroiss M; Nakajo M; Mügge DO; Hahner S; Fassnacht M; Schirbel A; Bluemel C; Higuchi T; Papp L; Zsótér N; Buck AK; Bundschuh RA; Lapa C
    Endocrine; 2016 Sep; 53(3):791-800. PubMed ID: 27138903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
    Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
    Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?
    Iagaru A; Quon A; McDougall IR; Gambhir SS
    Mol Imaging Biol; 2006; 8(4):212-7. PubMed ID: 16724293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of FDG Positron Emission Tomography/Contrast--Enhanced Computed Tomography in Preoperative Staging and Postoperative Follow-up in Rectal Cancer Surgery.
    Omarov N; Uymaz DS; Kulle CB; Ozkan ZG; Azamat S; Keskin M; Bulut MT
    Pol Przegl Chir; 2022 Feb; 94(6):10-16. PubMed ID: 36468505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
    Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
    Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.